Independent Medical Education (IME) Program
Ionis Pharmaceuticals' IME Program funds independent education initiatives to advance clinical knowledge and care in hereditary angioedema and severe hypertriglyceridemia.
Funder: Ionis Pharmaceuticals
Due Dates: Rolling; submit at least 60 days before program/event start date
Funding Amounts: No set maximum; funding based on program scope, budget, and alignment with priorities
Summary: Supports independent, evidence-based medical education initiatives in hereditary angioedema and severe hypertriglyceridemia to improve clinical care and awareness.
Key Information: Grants are only available to organizations, not individuals or private practices.
Description
Ionis Pharmaceuticals' Independent Medical Education (IME) Program funds unbiased, high-quality educational initiatives aimed at advancing clinical care and disease awareness in hereditary angioedema (HAE) and severe hypertriglyceridemia (sHTG), including familial chylomicronemia syndrome (FCS). Supported programs must be fair-balanced and independent, with the applicant organization maintaining full control over content and faculty, in line with ACCME standards for accredited activities. The IME Program does not support individual healthcare providers or private practices, focusing instead on organizational applicants such as hospitals, universities, and professional societies. The intent is to foster improved clinical knowledge and multidisciplinary management within the medical community.
